Involvement of platelet-activating factor in glutamate-induced neurotoxicity
Involvement of platelet-activating factor in glutamate-induced neurotoxicity
批准号:
12671344
负责人:
HIRASHIMA Yutaka
金额:
$1.79万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2002
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Using an adenoviral vector, we induced overexpression of the plasma type of platelet-activating factor acetylhydrolase (PAFacetylhydrolase) in cultured rat neurons. Neurons overexpressing this enzyme showed a decrease in glutamate-induced injury, mainly, apparent as decreased apoptosis. Reduction of lipid peroxidation by this enzyme and protection of mitochondrial function were demonstrated, and these may be the basis of the resistance to glutamate-induced neuronal injury that we observed.The efficacy and safety of a new platelet-activating factor receptor antagonist, E5880, were investigated for preventing cerebral vasospasm after subarachnoid hemorrhage (SAH) in 71 patients with SAH who underwent surgery for ruptured aneurysms within 3 days. Intravenous E5880 administration (300μg or 1200μg twice daily) was begun within 4 days and continued for 14 days. The incidence of symptomatic vasospasm, low-density area on computed tomography, and angiographic vasospasm was lower than in placeb … More o groups in previous studies. Clinical outcome was favorable compared with previous studies. No clinically important adverse events were observed. These results suggest that E5880 is safe and effective in the treatment of patients with cerebral vasospasm due to SAH.Etizolam, an anti-anxiety agent which is an antagonist of platelet-activating factor (PAF) receptors, was administered to patients with chronic subdural hematoma (CSH) after hematoma removal to assess the effectiveness for preventing recurrence compared with control patients not given the drug after surgery. The remaining volumes of subdural hematomas on brain computed tomography were measured approximately 1 month after removal. Volumes in the etizolam group were significantly smaller than those in the control group. Hematoma recurrence was not detected in the etizolam group 3 months after surgery, but was significantly more frequent in the control group. Etizolam administration may be useful for the prevention of recurrence of CSH. Less
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Hirashima Y: "Effect of a platelet-activating factor receptor antagonist E5880, on cerebral vasospasm after anaouyswel subaraelnoid hemorrylege"Neurol Med Chir (Tokyo). 41. 165-176 (2001)
Hirashima Y:“血小板激活因子受体拮抗剂 E5880 对 anaouyswel 蛛网膜下腔出血后脑血管痉挛的影响”Neurol Med Chir(东京)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hirashima Y, Takashima S, Matsumura N, Kurimoto M, Origasa H, Endo S: "Right sylvian fissure subarachnoid hemorrhage has electrocardiographic consequences"Stroke. 32. 2278-2281 (2001)
Hirashima Y、Takashima S、Matsumura N、Kurimoto M、Origasa H、Endo S:“右外侧裂蛛网膜下腔出血具有心电图后果”中风。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hirashima Y, et al.: "Transfection of the plasma-type platelet-activating factor acetylhydrolase gene attenuates glutamate-indced apoptosis in caltured rat cortical neurous."Brain Res. 885. 128-132 (2000)
Hirashima Y 等人:“血浆型血小板激活因子乙酰水解酶基因的转染可减弱培养大鼠皮质神经细胞中谷氨酸诱导的细胞凋亡。”Brain Res。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hirashima Y.,Ueno H.,Karasawa K,Yokoyama K,Setaka M.,Takaku A: "Transfection of plasma-type platelet-activating factor a cetyl hydrolase gene attenuates glutamate-induced apoptosis in cultured rat cortical neuroas"Brain Res. 885(1). 128-132 (2000)
Hirashima Y.、Ueno H.、Karasawa K、Yokoyama K、Setaka M.、Takaku A:“血浆型血小板激活因子 a 十六烷基水解酶基因的转染可减弱培养的大鼠皮质神经元中谷氨酸诱导的细胞凋亡”Brain Res。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hirashima Y, et al.: "Etigolam, an anti-anxiety agant, athennates recurrence of chronic subdural hematoma - Evaluation by comptued tomo graphy -"Neurol Med Chir (Tokyo). 42. 53-56 (2002)
Hirashima Y 等人:“Etigolam,一种抗焦虑剂,可预防慢性硬膜下血肿复发 - 通过计算机断层扫描进行评估 -”Neurol Med Chir(东京)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 13 条
Lipid peroxidation and PAFacetylhydrolase activity of cerebrospinal fluid in patients with subarachnoid hemorrhage
-
批准号:20591696
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2008
-
负责人:HIRASHIMA Yutaka
-
依托单位:
Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in neuronal sultures
-
批准号:07671504
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1995
-
负责人:HIRASHIMA Yutaka
-
依托单位:
国内基金
海外基金
登录
查看更多内容
双硫仑结合并抑制谷氨酸脱氢酶1活性调节Th17/Treg细胞平衡的作用与机制探究
-
批准号:82371755
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:王秦兰
-
依托单位:
石斛有效成分毛兰素靶向GGT7-GSH/Glutamate信号轴增强索拉非尼诱导的铁死亡逆转肝癌索拉非尼耐药的机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:陈鹏
-
依托单位:
孕激素通过下丘脑Glutamate信号通路抑制LH峰的机制研究
-
批准号:82001502
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:刘亚丽
-
依托单位:
BF区GABA-Glutamate-Ach神经微环路在麻醉-觉醒调控中的作用机制研究
-
批准号:81571351
-
项目类别:面上项目
-
资助金额:67.0万元
-
批准年份:2015
-
负责人:董海龙
-
依托单位:
穴位埋线调节围绝经期惊恐障碍患者脑神经活动Glutamate-GABA机制的在体研究
-
批准号:81473755
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2014
-
负责人:陈贵珍
-
依托单位:
小胶质细胞通过缝隙连接释放过量谷氨酸的机制研究
-
批准号:81301092
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:梁剑峰
-
依托单位:
谷氨酸的耳蜗毒性机制及干预研究
-
批准号:81070783
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:龚树生
-
依托单位:
囊泡谷氨酸转运体作为老年痴呆症药物新靶标的研究
-
批准号:30973541
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2009
-
负责人:程肖蕊
-
依托单位:
内毛细胞损伤动物模型的建立及其听觉电生理学研究
-
批准号:30872858
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2008
-
负责人:龚树生
-
依托单位:
重明益损汤对大鼠视网膜神经细胞凋亡的影响
-
批准号:30772823
-
项目类别:面上项目
-
资助金额:27.0万元
-
批准年份:2007
-
负责人:韦企平
-
依托单位: